<?xml version="1.0" encoding="UTF-8"?>
<ref id="B33-pharmaceuticals-14-00381">
 <label>33.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ou</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Lei</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Mi</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Ren</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Guo</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Guo</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Hu</surname>
    <given-names>J.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title>
  <source>Nat. Commun.</source>
  <year>2020</year>
  <volume>11</volume>
  <fpage>1620</fpage>
  <pub-id pub-id-type="doi">10.1038/s41467-020-15562-9</pub-id>
  <pub-id pub-id-type="pmid">32221306</pub-id>
 </element-citation>
</ref>
